| 0.4726 -0.022 (-4.53%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.15 |
1-year : | 1.53 |
| Resists | First : | 0.98 |
Second : | 1.3 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.46 |
Second : | 0.38 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.69 |
| MA(100) : | 1.36 |
MA(250) : | 3.61 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 4.2 |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 15.85 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SPRC ] has closed above bottom band by 2.8%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.51 |
| Low: | 0.46 - 0.46 | 0.46 - 0.46 |
| Close: | 0.47 - 0.47 | 0.47 - 0.48 |
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Tue, 23 Jul 2024
Scisparc hits 52-week low, trading at 0.595 USD - Investing.com
Tue, 23 Jul 2024
SciSparc’s Subsidiary Advances in Lung Cancer Therapy - TipRanks
Mon, 22 Jul 2024
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer - GlobeNewswire
Wed, 17 Jul 2024
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million - StockTitan
Tue, 16 Jul 2024
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification - StockTitan
Tue, 16 Jul 2024
SciSparc Ltd. Faces Nasdaq Delisting Over Bid Price - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.5 (%) |
| Shares Short | 48 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -14.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.77 |
| Profit Margin | -178 % |
| Operating Margin | -309.4 % |
| Return on Assets (ttm) | -33.2 % |
| Return on Equity (ttm) | -73.4 % |
| Qtrly Rev. Growth | -32.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.88 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0.53 |
| Price to Cash Flow | -0.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|